Google
IVA — INVENTIVA SA (Healthcare >> Biotechnology)
IVA FAQ
What is IVA's ROE?
INVENTIVA SA reports a Return on Equity (ROE) of 2,290.08%.
What is IVA's dividend yield?
INVENTIVA SA offers a dividend yield of 0.00%.
What is IVA's Deepscope Quality Score?
Deepscope rates IVA's overall financial quality at 62 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy IVA?
Deepscope's AI Timing Score for IVA is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does IVA belong to?
INVENTIVA SA is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 4.03
Price
-0.20
(-4.73%)
Day Change
|
|
|---|
IVA, ファンダメンタルスコアはok ( ファンダメンタル = 62) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- NEUTRAL
- Signal Description
- Company financial health is OK
- Reason
-
ROAが低い
ROAがROEに比べて低い
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not quite good , financial health is not good , and ability to make profit is ok , ...
| Deepscope 分析 |
|
51% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 88 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 4.03 |
| PBV / Sector |
-30.44 / 4.63
|
| Earning Per Share | -3.03 |
| PE / Sector |
N/A / 17.43
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
2.37 M
GREAT
|
| Average 1W Daily Value |
5.78 M
GREAT
|
| Timing Factors |
|
28% |
| Financial Health |
|
41% |
| ポイントになる統計 |
|
64% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-06-06 09:08:47 |
| Symbol | IVA |
| Name | INVENTIVA SA |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 208.95 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 883.85 / 8,857.28 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 50 rue de Dijon, Daix, France, 21121
Phone: 33 3 80 44 75 00
Website: https://inventivapharma.com
Employees: 69
Sector: Healthcare >> Biotechnology
Description: Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. Inventiva S.A. was incorporated in 2011 and is headquartered in Daix, France.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
